Journal
DRUG NEWS & PERSPECTIVES
Volume 19, Issue 1, Pages 27-31Publisher
PROUS SCIENCE, SAU-THOMSON REUTERS
DOI: 10.1358/dnp.2006.19.1.965871
Keywords
-
Categories
Funding
- NATIONAL CANCER INSTITUTE [R01CA093708] Funding Source: NIH RePORTER
- NCI NIH HHS [R01 CA093708-02, R01 CA093708] Funding Source: Medline
Ask authors/readers for more resources
Wnt-1 was first identified as a proto-oncogene activated in mouse mammary tumors induced by mouse mammary tumor virus in 1982. Wnt-1 signal is a secreted glycoprotein that plays important roles in embryonic development and carcinogenesis. In a conditional Wnt-1 transgenic mouse tumor model, reduction of Wnt-1 signaling results in the regression of the Wnt-1 initiated primary mammary tumors and lung metastasis. Aberrant activation of the Writ pathway has been strongly linked to the development of human cancers. Increased Wnt-1 signal has been found in a variety of human cancers. Our group has shown that blockade of Wnt-1 signaling, by either Wnt-1 small interference RNA or anti-Wnt-1 antibody induces apoptosis in human cancer cells and inhibits tumor growth in vivo. This review summarizes the recent significant findings and the potentials of Wnt-1 signal as a new therapeutic target for cancer. (C) 2006 Prous Science. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available